These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19304304)

  • 41. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.
    Hu C; Saenz DT; Fadel HJ; Walker W; Peretz M; Poeschla EM
    J Virol; 2010 Nov; 84(22):11981-93. PubMed ID: 20844042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
    Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
    Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    Han Y; Wang X; Dang Y; Zheng YH
    PLoS Pathog; 2008 Jul; 4(7):e1000095. PubMed ID: 18604271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.
    Vetter ML; Johnson ME; Antons AK; Unutmaz D; D'Aquila RT
    PLoS Pathog; 2009 Feb; 5(2):e1000292. PubMed ID: 19197360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CEM-T4 cells do not lack an APOBEC3G cofactor.
    Haché G; Harris RS
    PLoS Pathog; 2009 Jul; 5(7):e1000528. PubMed ID: 19649317
    [No Abstract]   [Full Text] [Related]  

  • 47. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pokeweed antiviral protein restores levels of cellular APOBEC3G during HIV-1 infection by depurinating Vif mRNA.
    Krivdova G; Hudak KA
    Antiviral Res; 2015 Oct; 122():51-4. PubMed ID: 26275799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
    Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
    Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
    Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
    Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    Kaiser SM; Emerman M
    J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells.
    Vetter ML; D'Aquila RT
    J Virol; 2009 Sep; 83(17):8646-54. PubMed ID: 19535442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain.
    Feng Y; Chelico L
    J Biol Chem; 2011 Apr; 286(13):11415-26. PubMed ID: 21300806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study.
    Hosseini I; Mac Gabhann F
    PLoS One; 2013; 8(5):e63984. PubMed ID: 23724012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    Liu B; Yu X; Luo K; Yu Y; Yu XF
    J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [HIV Restriction Factor APOBEC3G and Prospects for Its Use in Gene Therapy for HIV].
    Tikhonov AS; Mintaev RR; Glazkova DV; Bogoslovskaya EV; Shipulin GA
    Mol Biol (Mosk); 2022; 56(4):546-556. PubMed ID: 35964311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.
    Casartelli N; Guivel-Benhassine F; Bouziat R; Brandler S; Schwartz O; Moris A
    J Exp Med; 2010 Jan; 207(1):39-49. PubMed ID: 20038599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
    Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
    Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.